Amneal has added a further treatment to its complex generics portfolio after gaining US Food and Drug Administration approval for its abbreviated new drug application for a generic version of TobraDex (dexamethasone/tobramycin) 0.3%/0.1% ophthalmic suspension.
The approval comes as Amneal is actively pursuing higher-margin products – including complex dosage forms, drug-device combinations and other high-value...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?